Merck & Company Inc (MRK)
$128.11+2.12%
Spriggl Score: Moderate— sign in to explore; full breakdown with Premium
Last 30 trading days
Spriggl AI Verdict
“World-leading cancer franchise adding new approvals; patent expiry in 2028 creates a real but manageable earnings challenge.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About Merck & Company Inc
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerba…
- Sector:
- Healthcare
- Industry:
- Drug Manufacturers - General
- Market Cap:
- $281.2B
Recent dividends
- 15 Jun 2026$0.85
- 16 Mar 2026$0.85
- 15 Dec 2025$0.85
Get the full Spriggl analysis — free
A free Spriggl account gets you the screener, a watchlist, AI verdicts and a free full report every day — across Merck & Company Inc and 1,500+ UK and US stocks. The full score breakdown and AI analysis come with Premium.
Start free